As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
Biotechnology company Eikon Therapeutics announced the initial closing of a $350.7 million Series D financing round that it will use to advance its clinical-stage programs. The new funding brings the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results